Medicine and Dentistry
Radiation Therapy
100%
Malignant Neoplasm
86%
Head and Neck Cancer
53%
Neoplasm
46%
Chemoradiotherapy
42%
Overall Survival
37%
Stereotactic Body Radiation Therapy
26%
Non Small Cell Lung Cancer
26%
Cancer Cell
18%
Prostatectomy
17%
Wart Virus
17%
Disease
17%
Neck
17%
Biochemical Recurrence
16%
Intensity Modulated Radiation Therapy
14%
Hazard Ratio
13%
T Cell
12%
Lymph Node
11%
Tumor Progression
11%
Progression Free Survival
11%
Immunotherapy
10%
Cytotoxic T-Cell
10%
Proton Therapy
10%
Multivariate Analysis
9%
Adjuvant Chemotherapy
8%
Carcinogenesis
8%
Anaplastic Thyroid Carcinoma
8%
Cancer
8%
Interleukin 6
8%
Oropharynx Carcinoma
8%
Conformal Radiotherapy
8%
Metastatic Carcinoma
8%
Chemotherapy
8%
Prostate Cancer
8%
Distant Metastasis
7%
Primary Tumor
7%
Cylindroma
7%
Unfolded Protein Response
7%
Programmed Cell Death
7%
Endoplasmic Reticulum Stress
7%
Recurrence Free Survival
7%
Oral Cancer
6%
Low Drug Dose
6%
Lung Cancer
6%
Prostate Specific Antigen
6%
Drug Megadose
6%
Logistic Regression Analysis
6%
Squamous Cell Carcinoma
6%
Acute Toxicity
5%
Image-Guided Radiation Therapy
5%
Keyphrases
Head-and-neck Cancer
60%
Radiotherapy
52%
Overall Survival
33%
National Cancer Database
32%
Tumor
31%
Database Analysis
26%
Stereotactic Body Radiotherapy
24%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
24%
High-risk Human Papillomavirus (HR-HPV)
23%
Radiation Therapy
20%
Chemoradiation
17%
Interleukin-6
17%
Prostatectomy
17%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
17%
Hazard Ratio
15%
Improved Survival
15%
Early-stage Lung Cancer
14%
Tumor Growth
14%
Head-and-neck
13%
Salvage Radiotherapy
13%
Metal-organic Frameworks (MOFs)
13%
Functional Outcome
13%
Intensity-modulated Radiotherapy
13%
Chemoradiotherapy
12%
Black Men
11%
LNCaP
11%
Multivariate Analysis
11%
T Cells
11%
Tumor Antigen
10%
Confidence Interval
10%
Checkpoint Blockade
10%
Cancer Cells
10%
Progression-free Survival
9%
Human Prostate Cancer Cell Lines
9%
Patterns of Care
9%
Survival Outcomes
9%
Irradiated Patients
8%
Anaplastic Thyroid Cancer
8%
Adjuvant Chemotherapy
8%
Notch Signaling
8%
Volume De-escalation
8%
Apoptosis
8%
Tumorigenesis
8%
Lung Cancer
8%
Unfolded Protein Response
8%
Definitive Radiotherapy
8%
Immunomodulatory
8%
Oral Tumor
8%
Programmed Death-ligand 1 (PD-L1)
8%
Prostate Bed
8%
